Semin Neurol 2010; 30(1): 097-101
DOI: 10.1055/s-0029-1245004
© Thieme Medical Publishers

Pearls: Multiple Sclerosis

Elliot M. Frohman1 , 2 , Benjamin M. Greenberg1
  • 1Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas
  • 2Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas
Further Information

Publication History

Publication Date:
01 February 2010 (online)

ABSTRACT

Multiple sclerosis (MS) affects more than 500,000 Americans, and it is commonly on the differential diagnosis associated with patient referrals to neurology offices. Diagnostically, there are several nuances to the established criteria. Understanding the usefulness of various tests and the potential diagnoses that can cause false-positives is critical when evaluating patients for possible MS. Furthermore, recognizing various possible mimics in given situations will help practitioners avoid unnecessary treatment of patients. Once diagnosed, MS patients have a multitude of possible symptoms that they can experience, and rely on their neurologists to have an understanding of the potential interventions. Finally, there are various therapies currently available for disease modification. Developing a reasonable treatment algorithm that can be applied to patients is important when presenting patients with the various options. This article summarizes some of the pearls and pitfalls associated with the evaluation and management of patients with relapsing-remitting multiple sclerosis.

REFERENCES

  • 1 Aronson K J. Quality of life among persons with multiple sclerosis and their caregivers.  Neurology. 1997;  48(1) 74-80
  • 2 Polman C H, Reingold S C, Edan G et al.. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”.  Ann Neurol. 2005;  58(6) 840-846
  • 3 Comi G. Clinically isolated syndrome: the rationale for early treatment.  Nat Clin Pract Neurol. 2008;  4(5) 234-235
  • 4 Goodin D S, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.  Mult Scler. 2009;  , September 8 (Epub ahead of print)
  • 5 Hintzen R Q, Giovannoni G. CSF analysis in suspected MS: do bands aid?.  Neurology. 2008;  70(13 Pt 2) 1059-1060
  • 6 Davis S L, Frohman T C, Crandall C G et al.. Modeling Uhthoff’s phenomenon in MS patients with internuclear ophthalmoparesis.  Neurology. 2008;  70(13 Pt 2) 1098-1106
  • 7 Keegan M, König F, McClelland R et al.. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.  Lancet. 2005;  366(9485) 579-582
  • 8 Armas L A, Hollis B W, Heaney R P. Vitamin D2 is much less effective than vitamin D3 in humans.  J Clin Endocrinol Metab. 2004;  89(11) 5387-5391

Elliot M FrohmanM.D. Ph.D. 

Professor of Neurology and Ophthalmology, Department of Neurology, University of Texas Southwestern Medical Center at Dallas

5323 Harry Hines Blvd., Dallas, TX 75390-8806

Email: elliot.frohman@utsouthwestern.edu